FDA Approves First Wegovy Pill for Chronic Weight Management

Overview

• The approval covers adults with obesity or with overweight plus at least one related health condition.
• A 64-week trial of the 25 mg daily pill showed roughly 16.6% average weight loss versus 2.7% with placebo.
• Novo says U.S. availability begins in early January 2026, with manufacturing in North Carolina and inventory built for broad supply.
• Investor reaction was strong, with Novo shares rising about 8–10% after the announcement in U.S. and Danish trading.
• Eli Lilly is pursuing a competing oral drug that could gain approval by March 2026, while a reported U.S. agreement could price Novo’s pill from $150 per month.